Product Pipeline

Xenon is focused on advancing our ion channel neurology pipeline.

The products within our novel proprietary pipeline – including clinical-stage candidates XEN496 and XEN1101 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.